EQS-News: Quantumzyme Signs MOU With Zummit Africa to Establish a Centre of Excellence in AI for Green Chemistry

SAN DIEGO, CA - April 4, 2025 (NEWMEDIAWIRE) - Quantumzyme Corp. (OTC:QTZM), a pioneering biotechnology company specializing in computational enzyme engineering, has signed a Memorandum of Understanding (MOU) with Zummit Africa to establish a Centre of Excellence in AI for Green Chemistry. This collaboration will leverage artificial intelligence and machine learning to drive next-generation sustainable solutions in the chemical and pharmaceutical industries.

This deal brings together two pioneering organizations:

• Quantumzyme specializes in biocatalysis and enzyme engineering to develop clean, green chemical processes. Its cutting-edge quantum mechanics, molecular modeling, and AI-driven enzyme design have led to an in-progress novel biocatalyst for Ibuprofen API production, setting a new standard for sustainable pharmaceutical manufacturing.
• Zummit Africa is a leading community-driven AI and data science learning platform, dedicated to empowering individuals and organizations through innovative, real-world AI applications. With expertise in machine learning and digital transformation, Zummit Africa provides the ideal technological backbone for AI-driven breakthroughs in green chemistry.

The Centre of Excellence in AI for Green Chemistry will focus on:

• AI-driven biocatalysis - Enhancing enzyme activity, selectivity, and specificity for more efficient, eco-friendly chemical processes.
• Sustainable API production - Optimizing biocatalysts for pharmaceutical applications, including the greener synthesis of Ibuprofen.
• Data-driven molecular modeling - Using AI to predict enzyme behavior and accelerate the discovery of novel biotransformation solutions.
• Industry-academia collaborations - Bridging the gap between research, industry needs, and workforce development in sustainable chemistry.

“We are thrilled to partner with Zummit Africa to integrate AI into green chemistry, accelerating the transition to sustainable industrial processes,” stated Naveen Kulkarni, CEO of Quantumzyme. “This Centre of Excellence will be a game-changer in the field, combining Quantumzyme’s expertise in biocatalysis with Zummit Africa’s strength in AI and machine learning.”

“Zummit Africa is committed to driving AI-powered innovation that makes a real-world impact,” continued Kulkarni. “This partnership allows us to tackle one of the most pressing challenges of our time- sustainable chemical manufacturing- and shape the future of green chemistry.”

For the most current information and updates, please visit our website at www.quantumzymecorp.com.

About Zummit Africa

Zummit Africa is a leading AI and data science education platform, dedicated to empowering individuals and organizations with cutting-edge AI and machine learning solutions. With a focus on real-world applications, Zummit Africa is driving AI-led transformations across industries. For additional information about Zummit Africa, please visit www.zummitafrica.com.

About Quantumzyme Corp.

Quantumzyme Corp. is a pioneering biotransformation company revolutionizing chemical processes through sustainable, enzyme-based solutions. Specializing in green chemistry, it harnesses quantum mechanics, molecular modeling, AI-driven simulations, and computational enzyme engineering to design high-performance biocatalysts that enhance efficiency, reduce waste, and minimize environmental impact. By integrating computational modeling with wet-lab validation, Quantumzyme delivers scalable, cost-effective biocatalysis solutions that improve industrial sustainability. Offering end-to-end enzyme development services- from discovery and engineering to process optimization and scale-up—Quantumzyme empowers its partners to adopt greener, more efficient production methods. Committed to sustainability and innovation, the company envisions a future where biotechnology drives global solutions for climate change, pollution, and resource efficiency, making eco-friendly biocatalysis the industry standard.

Disclaimer

The information contained in this press release is provided by Quantumzyme Corp. (“Quantumzyme”) for general informational purposes only. This release may include forward-looking statements that reflect Quantumzyme’s current expectations, estimates, projections, and assumptions about future events, business performance, market conditions, or technological developments. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied in such statements. Forward-looking statements are based on management’s beliefs and assumptions as of the date of this press release and are subject to change without notice.

Quantumzyme makes no representations or warranties, express or implied, regarding the accuracy, completeness, or reliability of the information contained herein. The company undertakes no obligation to publicly update or revise any forward-looking statements as a result of new information, future developments, or changes in expectations, except as required by applicable law. Past performance should not be taken as an indicator of future results, and readers should not place undue reliance on any projections or expectations presented in this release.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities, nor does it provide financial, investment, or legal advice. Any references to market trends, scientific advancements, or industry insights are provided for contextual purposes only and should not be interpreted as endorsements, guarantees, or definitive predictions of future developments. Readers and investors are encouraged to conduct their own due diligence and seek independent professional advice before making any investment or business decisions related to Quantumzyme or its affiliates.

Media Contact:

Naveen Kulkarni
Chief Executive Officer
Quantumzyme Corp.
15656 Bernardo Center Drive, Suite 801
San Diego, CA 92127
Phone: +1 (858) 203-0312
Email: info@quantumzymecorp.com
Website: www.quantumzymecorp.com

View the original release on www.newmediawire.com

News Source: Quantumzyme Corp